140 filings
DEFA14A
HUMA
Humacyte Inc
29 Apr 24
Additional proxy soliciting materials
7:16am
DEF 14A
HUMA
Humacyte Inc
Definitive proxy
29 Apr 24
7:12am
S-8
HUMA
Humacyte Inc
28 Mar 24
Registration of securities for employees
8:55am
10-K
2023 FY
HUMA
Humacyte Inc
Annual report
28 Mar 24
8:06am
8-K
HUMA
Humacyte Inc
22 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
7:06am
8-K
ycyqyhs
4 Mar 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
6:53am
424B5
7lxn0f
1 Mar 24
Prospectus supplement for primary offering
4:05pm
424B5
2gqvh9t
29 Feb 24
Prospectus supplement for primary offering
4:11pm
8-K
gvnxzhmvn3j7 auk5lj
29 Feb 24
Other Events
4:02pm
8-K
8tpx 3glw
9 Feb 24
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
8:06am
8-K
5g6x6 vvbx8leljctlwa
12 Dec 23
Other Events
8:06am
8-K
ezvcymej y3qe2u
9 Nov 23
Humacyte Third Quarter 2023 Financial Results and Business Update
4:07pm
8-K
e76rar9466n8
12 Sep 23
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
7:09am
8-K
qfs7lbqx1k
14 Aug 23
Humacyte Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
535c4t
26 Jul 23
Humacyte Completes Enrollment in Phase 2/3 Trial of
8:07am
424B3
yhfzz67px86
22 Jun 23
Prospectus supplement
6:50am
EFFECT
9nx3p qvlotrctc0d50r
22 Jun 23
Notice of effectiveness
12:15am
CORRESP
838fy7o3o4kur 0z
16 Jun 23
Correspondence with SEC
12:00am